NORVIR Drug Patent Profile
✉ Email this page to a colleague
When do Norvir patents expire, and when can generic versions of Norvir launch?
Norvir is a drug marketed by Abbott and Abbvie and is included in five NDAs.
The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ritonavir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norvir
A generic version of NORVIR was approved as ritonavir by CIPLA on January 15th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NORVIR?
- What are the global sales for NORVIR?
- What is Average Wholesale Price for NORVIR?
Summary for NORVIR
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 109 |
Clinical Trials: | 95 |
Patent Applications: | 4,162 |
Drug Prices: | Drug price information for NORVIR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NORVIR |
What excipients (inactive ingredients) are in NORVIR? | NORVIR excipients list |
DailyMed Link: | NORVIR at DailyMed |
Recent Clinical Trials for NORVIR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pyramid Biosciences | Phase 1 |
Pardes Biosciences, Inc. | Phase 1 |
Soroka University Medical Center | Phase 3 |
Pharmacology for NORVIR
US Patents and Regulatory Information for NORVIR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbott | NORVIR | ritonavir | CAPSULE;ORAL | 020680-001 | Mar 1, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Abbvie | NORVIR | ritonavir | SOLUTION;ORAL | 020659-001 | Mar 1, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Abbvie | NORVIR | ritonavir | CAPSULE;ORAL | 020945-001 | Jun 29, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Abbvie | NORVIR | ritonavir | POWDER;ORAL | 209512-001 | Jun 7, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Abbvie | NORVIR | ritonavir | TABLET;ORAL | 022417-001 | Feb 10, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NORVIR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | NORVIR | ritonavir | TABLET;ORAL | 022417-001 | Feb 10, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | NORVIR | ritonavir | CAPSULE;ORAL | 020945-001 | Jun 29, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | NORVIR | ritonavir | SOLUTION;ORAL | 020659-001 | Mar 1, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | NORVIR | ritonavir | CAPSULE;ORAL | 020945-001 | Jun 29, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | NORVIR | ritonavir | CAPSULE;ORAL | 020945-001 | Jun 29, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | NORVIR | ritonavir | CAPSULE;ORAL | 020945-001 | Jun 29, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for NORVIR
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Mylan S.A.S | Ritonavir Mylan | ritonavir | EMEA/H/C/004549 Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older). |
Authorised | yes | no | no | 2017-11-09 | |
AbbVie Deutschland GmbH Co. KG | Norvir | ritonavir | EMEA/H/C/000127 Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older). |
Authorised | no | no | no | 1996-08-25 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for NORVIR
See the table below for patents covering NORVIR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Greece | 950300059 | ⤷ Sign Up | |
Poland | 2206500 | ⤷ Sign Up | |
New Zealand | 560829 | A solid pharmaceutical dosage formulation | ⤷ Sign Up |
Peru | 20100123 | UNA FORMULACION SOLIDA DE DOSIFICACION FARMACEUTICA | ⤷ Sign Up |
South Korea | 100187613 | ⤷ Sign Up | |
Austria | 196761 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NORVIR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0674513 | C300060 | Netherlands | ⤷ Sign Up | PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320 |
0674513 | SPC/GB01/044 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320 |
0674513 | C00674513 | Switzerland | ⤷ Sign Up | PRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |